p16、nm23H1在淋巴瘤中的表达及临床意义

目的：探讨p16、nm23H1在淋巴瘸组织的表达及其与淋巴瘸临床病理特征、疗效、生存率的关系，从而为临床治疗和判断预后提供新的依据。方法：采用免疫组化S—P法。结果：1.霍奇金淋巴瘤（HL）及非霍奇金淋巴瘸（NHL）p16、nm23H1表达差异无显著性。2．随淋巴瘸恶性程度的升高，p16表达减弱，nm23H1表达增强（P〈0．01）。3.P16低表达组完全缓解（CR）率低于p16高表达组，nm23H1低表达组CR率高于高表达组，差异均有显著性（P〈0．05）。4．p16高表达组与p16低表达组生存率差异无显著性（P〉0．05），nm23H1低表达组生存率高于nm23H1高表达组（P〈0．01）。结论：p16、nm23H1表达水平不仅可反映淋巴瘤的恶性程度，而且可作为淋巴瘤的预后指标。

THE EXPRESSION OF p16, nm23H1 IN LYMPHOMA AND THE CLINICAL MEANING

Objective: To detect the expression of p16,nm23H1 in malignant lymphoma cells and to elucidate its relation to the clinicopathological characteristics,chemotherapeutic response and survival rate,and therefore to provide a new theoretical basis for clinical treatment and predicting prognosis.Methods: Immunohistochemical technique,S-P method was used.Results: 1.There is not statistically significant difference between the expression of p16,nm23H1 in HL and that in NHL($P$>0.05).2.The expression of p16 was weakened,while the expression of nm23H1 was enhanced with the increase in the level of malignancy in NHL($P$<0.01).3. The CR rate in patients with high expression of p16 was far better than that in patients with low expression of p16($P$<0.05);the CR rate in patients with high expression of nm23H1 was far worse than that in patients with low expression of nm23H1($P$<0.05).4.The difference of survival rate between the group with p16 high expression and that with p16 low expression was not significant($P$>0.05);the survival rate in the group with nm23H1 low expression was significantly higher than that in the group with nm23H1 high expression($P$<0.01).Conclusion: p16,nm23H1 expression levels in malignant lymphoma can not only reflect its level of malignancy but also predict the prognosis.